Working at the cutting edge of cancer research and treatment, Nucleix utilizes bioinformatics and biochemical tools to develop noninvasive diagnostic tests, while publicly-traded VBL Therapeutics is focused on the discovery and development of products to attack cancer, through gene therapy, targeting an anti-inflammatory platform.
No less promising are the Israeli neuroscience companies attending the Bio Conference. Hailed as a technology pioneer by the World Economic Forum, ElMindA applies data analytics and machine learning to discover patterns in brain activity. Its solution carries promise as a diagnostic and monitoring tool for diseases like Alzheimer’s. Mitoconix develops disease-modifying therapeutics for neurodegenerative diseases including Alzheimer’s, Huntington’s, and Parkinson’s. The treatments have shown efficacy in animal models, and the company aims to initiate a human study soon.
Also represented will be BiomX, a microbiome drug discovery company whose treatments kill harmful bacteria in chronic diseases; CellCure, which harnesses human embryonic stem cells to replace dysfunctional cells in degenerative diseases; FutuRx, a biotech incubator that provides promising startups with an extensive support network; Pluristem, whose cell therapy products stimulate the body’s own regeneration and healing processes; and Taliaz, where researchers employ AI to generate therapy prediction reports, including for ascertaining the efficacy of different antidepressants.